Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: AXSM

Axsome Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for AXSM. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.74

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 13:41 UTC.

What Axsome Therapeutics, Inc. does

This company operates in pharmaceutical research and development, focusing on the discovery and development of drug products for various therapeutic areas. The company conducts clinical trials and seeks regulatory approvals from the FDA and comparable foreign authorities before commercializing products. Research and development is central to the company's business model, with ongoing investments in development programs across multiple stages.

Summarized from Axsome Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.74
Debt/equity1.42

Revenue, margins & earnings

FY2022: net loss $187M on revenue $50M$50MFY2022FY2023: net loss $239M on revenue $271M$271MFY2023FY2024: net loss $287M on revenue $386M$386MFY2024FY2025: net loss $183M on revenue $638M$638MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-03
  • 2026-09-03Chief Operating OfficerSale-10,000$2.09M
  • 2026-09-03Chief Operating OfficerOption exercise10,000$129.5K
  • 2026-09-03Chief Operating OfficerStock Option (Right to Buy)Option exercise-10,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Axsome Therapeutics, Inc. do?

This company operates in pharmaceutical research and development, focusing on the discovery and development of drug products for various therapeutic areas.

When did AXSM last file with the SEC?

Axsome Therapeutics, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-08-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:41 UTC. This page is also available as JSON at /api/data?ticker=AXSM and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AXSM and 5,000+ tickers.

Create a free account — keep AXSM
For your agent
GET /api/data?ticker=AXSM

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt